

ASX Release

Anatara Commences Second Detach™ Trial

Key points:

- **Second product registration trial commenced**
- **First weaners dosed with Detach™ in field trial**
- **Trial being conducted on major pig producer site**
- **Trial is designed to support the reduction of the use of antibiotics in livestock**
- **Manufacturing capability in place to supply major markets**
- **Product stability trials have commenced and are being conducted in parallel**
- **Potential to quickly move into major Asian markets post APVMA approval**
- **Company pursues additional growth opportunities**

BRISBANE, 18th June 2015: Anatara Lifesciences (ASX:ANR) is pleased to announce it has begun the second pivotal field trial of its lead product Detach™, a non-antibiotic, natural therapy to prevent and treat diarrhoea, in weaned pigs.

The second field trial is being conducted in a major commercial piggery and will support Anatara's application to register Detach™ for sale in Australia with the Australian Pesticides and Veterinary Medicines Authority (APVMA). Approval for sale of the product in Australia will open the opportunity to quickly register Detach™ for sale in major Asian markets.

A minimum of 560 weaners have been enrolled in this second study with results expected within the third quarter 2015. The first weaners have been dosed with Detach™ in a placebo controlled, parallel group, randomised and blinded study.

The trial will investigate the ability of Detach™ to reduce the incidence, severity and duration of diarrhoea, otherwise known as scour, compared to placebo. Scour will be assessed by a scour score that measures the incidence and severity of scour as weaner clinical condition. Other trial endpoints include increases in average daily weight gain as well as the reduction in antibiotic treatments.

The second trial has commenced using Detach™ manufactured under the code of good manufacturing practice (cGMP), and just under 500,000 doses at commercial scale have already been produced in line with registration requirements of the APVMA.

Anatara CEO Dr Paul Schober said: "We are confident in our ability to scale manufacturing to meet global demand. In assessing the registration requirements for Detach™ in a number of major Asian markets we are confident of a relatively straightforward approval process post successful registration in Australia."

Anatara Chief Scientific Officer (CSO) Dr Tracey Mynott said: "Detach™ has already been shown to be effective in preventing scour in piglets both in the first trial reported earlier this year and in earlier Australian and international field trials. Assuming this new trial data

supports the existing data, Anatara expects to submit its registration application for Detach™ in pigs with the APVMA in the fourth quarter 2015.”

There is an urgent need to reduce the use of antibiotics in animals because of the emergence of antibiotic resistance in bacteria. Antimicrobial resistance is a serious worldwide problem for animals, and is a growing issue that governments globally are grappling with.

“We continue to be excited that Detach™ can potentially make a significant contribution to reducing reliance upon the use of antibiotics for the control of diarrhoea in farm animals,” Dr Mynott said.

Anatara plans to run a third field trial, the start of which will be announced to the ASX immediately after commencement.

“Since listing in October 2014 the Anatara executive team continue to execute on its business plan and deliver on its key milestones. Increasing consumer momentum and positive developments with the relevant regulators in Australia and internationally are presenting a number of exciting opportunities for the company to explore in the near term,” Chairman Dr Mel Bridges said.

Anatara expects Detach™ to be on sale in 2016 based on the current pace of progress and with trial results supporting existing data. Launch into a number of Asian markets is targeted to follow shortly after.

Planning for the registration of Detach™ in Europe and the USA is well advanced and has been boosted with the recent appointment of internationally recognised authority Dr Kevin Woodward to head the regulatory team.

For more information please contact:

General inquiries

Dr Paul Schober
CEO, Anatara Lifesciences
+61 412 026 657
pschober@anataralifesciences.com

Media inquiries

Gavin Lower
Buchan Consulting
03 8866 1215
glower@buchanwe.com.au

About Anatara Lifesciences

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.